Pfizer and AstraZeneca seek new revenue streams as COVID subsides

Alena Butor/iStock via Getty Images

Although the COVID-19 pandemic has ended up being a cash cow for several pharmaceutical and biotech companies, many are looking for other treatments to focus on to replace revenues that are beginning to fade.


Leave a Reply

Your email address will not be published. Required fields are marked *